DEAR GOOGLE: I would be glad if you could please approve my site on Adsense as I link to the sources and I do a great deal of machine sorcery to rank, summarize and extract metadata from articles. Saying I infringe on copyright is the same as saying Google or Yahoo News are not legit. Thank you for reading.
[I have added the ad code to all pages, sorry for forgetting such an important thing]
this page has been updated 1 month ago

Herceptin


News

Global Cancer Immunotherapy Market: $100+ Billion Analysis & Forecast 2020-2023 -...

DUBLIN--(BUSINESS WIRE)--Dec 4, 2019--

discovered 5 months ago on Odessa American

Edited Transcript of GUD.TO earnings conference call or presentation 12-Nov-19 10:30pm GMT

On July 16, 2019, Health Canada approved NERLYNX for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant

discovered 5 months ago on Thomson Reuters StreetEvents via Yahoo Finance

Oncology Cancer Blockbuster Drugs Market Report : Global Industry Analysis, Size, Share, Growth,...

Top 27 Cancer Blockbuster Drugs Covered Under This Report Are: 1. Imbruvica 2. Revlimid 3. Pomalyst/Imnovid 4. Keytruda 5. Herceptin 6. Avastin 7. MabThera/Rituxan 8. Perjeta ...

discovered 5 months ago on Market Watch

The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer...

The following is a roundup of top developments in the biotech space over the last 24 hours: (Biotech...

discovered 5 months ago on Benzinga via Yahoo Finance

New Early Breast Cancer Drug Approved by Singapore Health Sciences Authority

A new breast cancer drug shown to significantly reduce the risk of cancer recurrence has received...

discovered 5 months ago on PR Newswire via Yahoo Finance

Puma Biotech Expands Pierre Fabre License to Add Countries

Puma Biotechnology, Inc. PBYI announced that it has amended and extended the terms of its license...

discovered 5 months ago on Zacks via Yahoo Finance

Trastuzumab-DM1 - 15 top blockbuster contenders

T-DM1's prospects keep shining, with clinical results presented at a recent cancer meeting in Stockholm adding to the resume of a drug that could be destined for stardom. Roche, the largest ...

discovered 5 months ago on FierceBiotech

Mylan and Biocon Launch Trastuzumab Biosimilar, Ogivri™ (trastuzumab-dkst), in the U.S.

(NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the U.S. launch of...

discovered 5 months ago on PR Newswire via Yahoo Finance


trendingNow

trendingYesterday

trending1week

Help and support - Sitemap - Go to top